Providers/Grant Support
This activity is supported by an independent education grant from Sanofi.
Credits Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This activity is designed to meet the educational needs of hematology and hemato-oncology.
Program Overview
Immune-mediated cytopenias such as immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) remain challenging to manage due to relapse risk, corticosteroid toxicity, and ongoing symptom burden. This CME activity reviews the underlying immune mechanisms driving these disorders and examines current treatment limitations. Faculty highlight emerging corticosteroid-sparing therapies—including BTK inhibitors, FcRn inhibitors, BAFF pathway inhibitors, complement inhibitors, and plasma cell-directed agents—and discuss how recent clinical data can inform personalized, mechanism-based treatment strategies. Emphasis is placed on improving durable disease control, reducing treatment-related toxicity, and enhancing patient quality of life.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Describe the pathogenesis of immune-mediated cytopenias, including immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA) to enhance the identification and understanding of these conditions.
- Understand and implement current corticosteroid-sparing approaches to improve efficacy, patient safety, and quality of life.
- Apply clinical data and mechanisms of action of new and emerging therapies to tailor treatment strategies in autoimmune cytopenias.
- Increase clinician confidence in integrating new and emerging therapies into practice.
Faculty
David J. Kuter, MD, DPhil
Hematology Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA, USA
Sandhya R. Panch, MD, MPH
Division of Hematology/Oncology
University of Washington
Seattle, WA, USA
Accreditation Statement
John Wiley & Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
John Wiley and Sons, Inc. designates this enduring CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity. For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.
Disclosure of Conflict of Interest
David J. Kuter
Research: Fulcrum, Novartis, Principia, Sanofi, Takeda
Consulting: Alexion, Alpine, Amgen, argenx, BioCryst, Blackstone, Bristol Myers Squibb, Cardurion, Caremark, Chugai, Cyrus, Hengrui, Hutchmed, Iconic Bio, Immunovant, Inmagenebio, Kaigen, Kyowa-Kirin, Lilly, Medscape, Merck Sharp Dohme, New York Blood Center, Nexcella, Novartis, Nurix, Nuvig, Ouro, Peerview, PER, Pfizer, Platelet Disorder Support Association, Principia, Regeneron, Rigel, Sanofi, Seismic, Sobi, Takeda, Timberlyne, UCB, Up-To-Date, Vertex, Verve.
Sandhya R. Panch
Consulting: Johnson and Johnson, Recordati Rare Diseases Inc., Sanofi
Instructions for Participation and Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be available for the participant to download.
Course Viewing Requirements
Supported Browsers:
Desktop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome
Supported Phones & Tablets:
All devices
Disclosure of Unlabeled Use
John Wiley and Sons, Inc. requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Contact Information
For CME questions please contact: [email protected]